Aspen Oss B.V. is proud to announce the extention of our cGMP Compliance for the production locations Diosite and Moleneind in Oss - The Netherlands. During the 4 days inspection from November 19th to November 22nd,
Oss, The Netherlands - JSE Limited listed Aspen Holdings, the ninth largest generic pharmaceutical company in the world, announced today that the Aspen Group ("Aspen") has finalized the acquisition of Active Pharmaceutical Ingredients (API) manufacturing operations and related businesses ("the API business") from MSD, known as Merck & Co., Inc. in the US and Canada.
Stephen Saad, Aspen Group Chief Executive, said "this deal strongly complements Aspen's strategic intent
Today is a special day for Aspen Oss, since our company was founded exactly 90 years ago. On July 9th 1923 we began our operations on API production by synthesis of insulin from animal tissue.
The Dutch Health Care Inspectorate has planned a next GMP inspection of our 2 API production locations in Oss-The Netherlands (Moleneind and Diosite) from November 19th to November 22nd 2013. As our current GMP certificate
On Thursday June 27th, 2013 MSD announced it signed a key agreement that marks a milestone in the negotiation of a transaction to sell the Oss API operations to South-African pharma company Aspen. The deal is expected to be finalized in the late third quarter or early fourth quarter of 2013 following the successful completion of negotiation and execution of additional necessary agreements and regulatory agency due diligence reviews.
The existing third party supply business will not be impacted by this proposed sale. Both MSD and Aspen are committed to ensuring continuity of supply to valued customers in this segment.
For more information please read the attached press release.